



PeptiDream

Revolutionizing Drug Discovery

FY 2026 1H
Financial Results Presentation
August 12, 2026

PeptiDream Inc.
(TSE : 4587)

AGENDA

BUSINESS UPDATE & HIGHLIGHTS

PDRadiopharma UPDATE

FINANCIAL UPDATE

INTRODUCTIONS of NEW EVPs

SUSTAINABILITY

CLOSING REMARKS

Q&A

Today's Speakers



Patrick C Reid
CEO



Masato Murakami
EVP: Radiopharma Business
President: PDRadiopharma



Catherine Ohura
EVP: Operations



Jun Kono
EVP: Strategy



Kodo Shikata
EVP: People & Culture

The Evolution of PeptiDream

Focus on Three Strategic Priorities to Drive our Transformation



Expansion/Advancement of Clinical-Stage Pipeline

- Increasing overall number of programs in clinical pipeline; **main driver of future revenue & corporate value.**
- Clinical development of wholly-owned programs to compliment collaboration partnered clinical programs.



Robust Pipeline Diversified Across 5 Core Focus Areas

- Advancing a broad range of preclinical and clinical programs across five therapeutic areas where macrocyclic peptides offer significant advantages.
- Asset creation engine to support further **clinical pipeline expansion** as well as **new partnering / out-licensing opportunities.**




Disciplined P&L and Cash Flow Management

- A focus on revenue from R&D funding and milestones from existing deals, upfront payments from new partnerships, as well as PDRadiopharma growth.
- **Maintain strict cost controls;** balancing R&D investment versus annual profitability & cash flow generation.

Clinical Pipeline Expansion — Driving Value Creation



Focus on Expanding RI and Non-RI Clinical Pipeline to Drive Future Revenue Growth



Our 5 Core Focus Areas — A Wealth of Opportunities



Creating a stable and diversified revenue base from multiple business opportunities

Radiopharma “RI” Business

✓ Rapidly growing clinical pipeline!

- Currently 13 programs in clinical development spanning phases.
- **Japan**; PSMA¹⁾, ATSM²⁾
- **Partnered**; GPC3, FAP, HER2, etc.
- **In-House**; CA9


✓ Robust preclinical pipeline, both In-House & Partnered.

- Top pharma partners in field
- In-House; CLDN18.2, CDH3, etc.
- Asset creation engine


✓ Strong foundation and PET market growth in Japan Radiopharma business.

✓ Multiple business opportunities exist across our RI efforts

- New partnerships/in-licensing (Japan)
- New partnerships/out-licensing (ex-Japan)



5 Core Areas of Focus



Peptide “non-RI” Business

✓ Steady progress across a wide range of programs including oral!

- Currently 6 programs in clinical development – all partnered programs.
- Exciting partnered preclinical programs moving toward clinical stage.
- **Internal asset creation** – IL17, myostatin, etc., provide option flexibility

✓ Robust preclinical pipeline of partnered Oligo-PDC programs progressing toward clinical development.

- Roster of top pharma partners in field
- **Advancing toward clinical entry**
- High interest in new partnering

✓ Major partnership progressing well.

- **Advancing toward clinical entry**
- High interest in new partnering

✓ Multiple business opportunities exist across our MPC efforts


- Internal asset creation
- High interest in new partnering

Our Five Core Focus Areas – Asset Creation Engine




Leverages the unique strengths of macrocyclic peptides across both internal and partnered efforts

1 Peptide-RI Conjugates




- ✓ **Ideal modality for targeted RI delivery**
- ✓ High target selectivity
- ✓ Excellent tumor penetration and retention
- ✓ Rapid clearance
- ✓ Versatile and scalable platform

2 Oral/ injectable Peptide Therapeutics




- ✓ One of hottest fields with 2 recent approvals validating the modality
- ✓ **Oral dosing with efficacy of injectable biologic**
- ✓ High systemic exposure with exceptional target selectivity and potency
- ✓ Favorable safety profile

3 Peptide-Oligo Conjugates




- ✓ Ideal delivery vehicles
- ✓ **Allow for precise tissue targeting**
- ✓ Enhanced cellular delivery
- ✓ Improved efficacy & safety
- ✓ Applicable across diverse targets & indications

4 Peptide-Cytotoxin Conjugates



- ✓ Ideal for tumor targeted delivery
- ✓ Builds on RI delivery concept & advantages
- ✓ Higher tumor-to-normal tissue exposure
- ✓ Access targets ADCs cannot
- ✓ Simple/scalable manufacturing


5 Multi-Functional Peptide Conjugates (MPC)




- ✓ Extends payload (RI, Oligo, Cytotoxin) delivery concept to recruiting/engaging
- ✓ Immune engagers – efficacy of biologics with potential safety advantages
- ✓ Powerful potential of bi- and tri-specific molecules with simplicity of peptides

FY2026 1H Highlights — 6 Programs Entered Clinical Pipeline

FY2026 Guidance for New Clinical Entries Already Achieved



Pipeline Overview: Radiopharmaceuticals



	Disease Area	Program	Partner		IND-enabling / Ph0	Ph1 (Escalation/Expansion)	Ph2/Ph3 (Registrational)	Development Stage	
								Japan	Overseas
Theranostics / Therapeutics	Malignant Brain Tumors	⁶⁴ Cu-ATSM	LinqMed	SM ² -RI				Ph3 Ongoing	—
	Prostate Cancer	¹⁷⁷ Lu-PSMA I&T ⁶⁴ Cu-PSMA I&T	Curium Pharma	SM-RI				Registrational Trial Initiated	Ph3 Completed ³⁾ Ph3 Ongoing
	Hepatocellular Carcinoma	²²⁵ Ac-GPC3 (RYZ801) ⁶⁸ Ga-GPC3 (RYZ811)	RayzeBio	P ⁴ -RI				Global Study Prep.	Ph1/1b Ongoing
	PDAC/NSCLC/BC/CRC	¹⁷⁷ Lu-FAP (FXX489/NNS309) ⁶⁸ Ga-FAP (FXX489/NNS309)	Novartis	P-RI				—	Ph1 Ongoing
	Renal Cell Carcinoma	²²⁵ Ac-CA9 (PD-32766T) ⁶⁴ Cu-CA9 (PD-32766D)	In-house	P-RI				Ph0 Completed	Ph1 Ongoing (US)
	BC/ NSCLC/ GEJ/ bladder cancer	[¹⁷⁷ Lu]Lu-DWJ155 [⁶⁸ Ga]Ga-DWJ155	Novartis	P-RI				Ph1 Ongoing	Ph1 Ongoing
	Gastric cancer	²²⁵ Ac-CLDN18.2 (PD-29875T) ⁶⁴ Cu-CLDN18.2 (PD-29875D)	In-house	P-RI				IND-enabling/ Ph0 Ongoing	—
	Head and Neck Cancer	²²⁵ Ac/ ¹⁷⁷ Lu-CDH3 ⁶⁴ Cu/ ⁶⁸ Ga-CDH3	In-house	P-RI				IND-enabling/ Ph0 Prep.	—
	Oncology	Not yet disclosed	RayzeBio	P-RI				—	Selected Clinical Dev. Candidate
	Oncology	Various Undisclosed programs	Various partners/ in-house	P-RI				Not Disclosed	Not Disclosed
Dx ⁽¹⁾	Various Cancers	¹⁸ F-PD-L1 (BMS-986229)	Bristol Myers Squibb	P-RI				—	Ph1 Completed
	Immune Function	Not yet disclosed	MSD ⁵⁾	P-RI					Ph1 Ongoing


Pipeline Overview: Peptide (non-RI)

→ 2026 Progress
 Updates from FY2025

	Disease Area	Program	Partner		Pre-clinical/ IND-enabling	Ph1	Ph2	Ph3	Development Stage	
									Japan	Overseas
Clinical Programs	Acromegaly	GhR Antagonist (ALXN2420)	AstraZeneca	 Peptide					—	Ph2 Ongoing
	Multiple Myeloma	CD38-ARM™ (BHV-1100 + NK)	Biohaven	 MPC					—	Ph1a/1b Completed
	COVID-19	S2-protein Inhibitor (PA-001)	PeptiAID	 Peptide					Clinical Research Completed	Ph1 Completed
	Not Disclosed	Merck (Not disclosed)	MSD ¹⁾	 Peptide					—	Ph1 Ongoing
	Inflammatory Diseases	Merck (Not disclosed)	MSD ¹⁾	 Peptide					—	Ph1 Ongoing
	Autoimmune Diseases	Selective TNFR1 inhibitor (AK1940)	Asahi Kasei Therapeutics	 Peptide					Ph1 Ongoing	—
Selected Preclinical Programs	Allergic Diseases	KIT Inhibitor (MOD-B)	Alivexis	 SM					IND-enabling	—
	Obesity/ Muscle Disorders	Oral Myostatin Inhibitor	In-house	 Peptide					Pre-clinical Obesity	—
	Inflammatory / Immunology	Oral IL-17A/F Inhibitor	In-house	 Peptide					Pre-clinical	—
	Inflammatory Diseases	Not yet disclosed	Johnson & Johnson	 Peptide					Pre-clinical	—
	Not Disclosed	Oral/ Peptide Therapeutics	Various Partners/ in-house	 Peptide					—	—
	Not Disclosed	Oligo-PDC	Various Partners	 Oligo-PDC					—	—
	Not Disclosed	Cytotoxic-PDC	MSD ¹⁾	 Cytotoxic-PDC					—	—
	Not Disclosed	MPCs (Immune Engagers, etc.)	In-house	 MPC					—	—

Major Clinical Pipeline Advances in FY2026 1H

Clinical development progress across in-house and partnered programs



PDRadiopharma: Commercial Strength into Future Product Value

Commercial growth provides a durable foundation, while late-stage assets and policy support future revenue

FY26 1H Radiopharma segment revenue: ¥8,025m (+¥242m YoY)



COMMERCIAL ENGINE

**+30% YoY PET Product
Revenue Growth**

**Durable commercial
foundation**




VALUE CATALYSTS

**^{64}Cu -PSMA I&T¹⁾ data
readout: FY2026 H2**

**^{177}Lu -PSMA I&T¹⁾
registrational study**

**^{64}Cu -ATSM²⁾
Ph3 registrational study**



STRATEGIC ENABLER

National policy recognition

**Development, manufacturing,
supply & healthcare
infrastructure**


**Improving commercialization
readiness**

PDRadiopharma combines a growing commercial base with late-stage assets and integrated capabilities that create a path to potential future product revenue in Japan.

Commercial Engine: PET Revenue Grew 30% YoY

Amyvid and FDG growth strengthen PDRadiopharma's commercial revenue base

PET products revenue growth



Key Growth Drivers

- **Amyvid**
Utilization expanding with the amyloid-treatment market
- **FDG**
Continued growth supported by flexible dosing
- **PET demand**
Broader utilization across diagnostic applications

PET growth strengthens PDRadiopharma's commercial foundation while supporting continued investment in late-stage programs.

Advancing Late-Stage Assets to Potential Product Revenue in Japan

Establishing an integrated diagnostic–therapeutic franchise in Japan

First diagnostic-therapeutic integrated PSMA franchise in prostate cancer

^{64}Cu -PSMA I&T¹⁾ (Dx²⁾)



Recurrence detection
Metastatic disease assessment
Patient selection for PSMA-targeted therapy

June 2026

Patient dosing completed

FY2026 H2 **NEAR-TERM CATALYST**

Data readout expected

FY2027

NDA planned

^{177}Lu -PSMA I&T¹⁾ (Tx³⁾)



Treatment of patients with post-
ARSI⁴⁾, pre-taxane mCRPC⁵⁾

February 2026

First patient dosed

Registrational study underway

FY2029

NDA planned

Second late-stage opportunity for future

^{64}Cu -ATSM⁶⁾



Therapeutic candidate for recurrent
malignant glioma

June 2024

First Patient Dosed

P3 Registrational study underway

FY2028

NDA planned

Potential future product revenue following successful development, regulatory approval and launch

PDRadiopharma is positioned to convert successful clinical assets into product revenue through its regulatory, manufacturing, supply and commercial capabilities in Japan.

Radiopharmaceuticals Recognized in Japan's National Policy

Growth Strategy and Honebuto Policy 2026 strengthen policy focus on RI-based medicines

JAPAN GROWTH STRATEGY



17 Strategic Sectors



No.11 Drug Discovery & Advanced Healthcare

A national priority for Japan's long-term competitiveness

Honebuto Policy 2026

RI-based medicines were highlighted as a priority area in Drug Discovery & Advanced Healthcare. (July 2026)

National priority



Explicit RI policy commitment

Policy developments

- *Honebuto Policy 2026*
Radiopharmaceuticals included in Japan's national policy agenda
- *Japan Atomic Energy Commission of Japan Cabinet Office*
Dedicated expert panel established in April 2026

RI-based medicines explicitly addressed

- RI supply-chain resilience
- Domestic manufacturing capabilities
- Treatment capacity and hospital infrastructure
- Coordination across the path to adoption


Investing in New Manufacturing Capacity for Future Proprietary Radiopharmaceutical Launches amid an Increasingly Supportive Policy Environment

Overview of FY2026 1H Consolidated Results

Consolidated Results (JPY M)	FY2025 Q2 Results	FY 2026 Q2 Results	YoY	FY2026 Forecasts
Revenue	8,543	9,226	+683	32,000
Drug Discovery and Development Business	760	1,201	+441	
Radiopharmaceutical Business	7,783	8,025	+242	
EBITDA	(1,609)	(1,409)	+200	
Operating Profit	(2,625)	(2,534)	+91	4,600
Profit attributable to owners of the Company	(2,122)	(1,999)	+123	3,000
Comprehensive Income	(2,122)	(2,005)	+116	
Earnings Per Share (JPY)	(16.40)	(15.51)	+0.89	

Reaffirmed FY 2026 Financial Guidance

Progress remains on track and our FY2026 guidance remains unchanged



*For each Major Internal Program we are focused on finding the **right partner** to both develop and maximize the value of each program.
+ α represents potential partnering/out-licensing deals that were not included in FY2026 guidance therefore representing potential upside.

Strong Cash Position to Execute Strategy



Investments in internal R&D programs, clinical development, and infrastructure/capability expansion

Investment in development of wholly-owned assets



Cash on hand **¥23.6bn**

- Expecting Cash position to strengthen further with new partnerships/deals in FY26 and FY27.
- Increase in R&D expenditures largely related to CA9, CLDN18.2, & PSMA clinical development costs as well as IL17, Myostatin, and MPC related research costs in FY26. (¥6.5 FY26 estimate vs ¥5.0 FY25 actual)
- Annual R&D budget/investment to be balanced versus annual revenue/profitability projections.

Investment in continued business expansion

New Research Building

Location: **Tonomachi, Kanagawa**

Timeframe: **2027 - 2029**

Investment: **¥ 12-15bn**



New Manufacturing Plant

Location: **Kazusa, Chiba**

Timeframe: **2027 - 2028**

Investment: **¥ 10-12bn**



- Both capital projects are expected to be funded through long-term bank loans at attractive rates
- Efforts underway to apply for various government incentive programs, certain tax benefits, as well as subsidy programs to offset costs

New Leadership Team from July 1



Patrick Reid
Representative Director & CEO



Masato Murakami
Board Director, EVP
(Radiopharma Business & Development)



Christian Cunningham
EVP (Research)



Catherine Ohura
EVP (Operations)



Jun Kono
EVP (Strategy)



Kodo Shikata
EVP (People & Culture)



Yen Ting Chen
VP (Business Development
& Alliance Management)



Naoki Kawamura
VP (Radiopharma
Business)



Taiki Kou
VP (Strategy &
Operations)



Kengo Miyagawa
VP (Finance)



Chieko Inoue
VP (Legal & Intellectual
Property)



Yuko Okimoto
VP (Corporate
Communications)

Welcoming New EVPs



Catherine Ohura, MS, PMP;
Executive Vice President:
Operations

- Representative Director and General Manager for Illumina Japan, leading business growth in Japan for Illumina products and services (Next Generation Sequencers, etc.).
- Representative Director and General Manager of Labcorp Laboratories Japan
- Chief Executive Officer (CEO) of the Global Health Innovative Technology (GHIT) Fund, driving international public-private partnerships in global health.
- Leadership experience from Bristol Myers Squibb (working in both, US headquarters and Japan affiliate), including leading large-scale global organizations both in R&D and Commercial organizations.
- Also serves as an External Director of Sugi Holdings Co., Ltd.



Jun Kono, MBA;
Executive Vice President:
Strategy

- Japan Commercial Head at Astellas Pharma, leading commercial strategy and operations in one of the company's key markets.
- Senior leadership roles based in the US and Europe for globalization of pharma business and execution of regional operations, in addition to leading global business development to shape R&D portfolio.
- Brings a combination of strong leadership track record of strategy, business development, commercial and global/regional operations in established global biopharma organization.
- Jun Kono has received his Master of Business Administration degree with honor from the University of Chicago Booth School of Business.



Kodo Shikata, PhD;
Executive Vice President:
People & Culture

- Head of Global HR Strategy at Eisai, leading company-wide initiatives to strengthen organizational effectiveness and global talent capabilities.
- Principal Scientist at Eisai Product Creation Systems in the Neurology Unit at its London research laboratory, following an early career in research.
- Holds a Ph.D. in medicine from Okayama University Graduate School of Medicine.

Sustainability as a Foundation for Next-Generation Medicines

Strengthening the Foundation for Sustainable Value Creation through Sustainability and Business Growth

Advancing Our Sustainability Initiatives

(Progress Since FY2025)



Governance
Enhanced Corporate Governance with a New Leadership Structure



Climate
80% of Group-wide Electricity Consumption Powered by Renewable Energy



Water
Set a 2030 Group-wide Water Reduction Target



People
Para Athlete Tsukimura Captured Gold Medal at the 2025 Wheelchair Rugby Asia-Oceania Championship

External Recognition Driven by Our ESG Performance



CDP 2025 Climate “A List”



FTSE JPX Blossom Japan Index
6 consecutive years



FTSE JPX Blossom Japan Sector Relative Index
5 consecutive years



Evaluates environmental disclosure and carbon efficiency

2024 CONSTITUENT MSCI JAPAN EMPOWERING WOMEN INDEX (WIN)
Gender Diversity Recognition

Note: FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirms that PeptiDream has been independently assessed according to the index criteria and has satisfied the requirements to become a constituent of the FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index. Created by the global index provider FTSE Russell, these indices are designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices, and are used by a wide variety of market participants to create and assess responsible investment funds and other products. THE INCLUSION OF PEPTIDREAM INC. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF PEPTIDREAM INC. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.

Q&A

Appendix

PeptiDream – Mission, Vision, Values

Striving towards fulfilling our Mission, achieving our Vision and delivering our Values

*As The Global Leading Peptide
Drug Discovery Company*



Mission

Our mission is to discover the next generation of transformational medicines that will drastically improve the lives of patients worldwide.

Vision

Our vision is to continue to uncover and expand on the power of macrocyclic peptides to unlock novel therapeutic and diagnostic possibilities through strong research and global collaboration.

Value

Our culture is anchored in the belief that every employee has the ability to be exceptional. We strive to create an environment where EXPERTISE is rewarded, PASSION is celebrated, and INTEGRITY is ingrained across every level of our organization.

PeptiDream Overview

PeptiDream and PDRadiopharma



Largest Biotech Company in Japan

- PeptiDream is a drug discovery company with a vertically integrated radiopharmaceutical subsidiary (**PDRadiopharma**) focused on the discovery, development, and commercialization of peptide-based therapeutics, peptide-drug conjugates, and radiopharmaceuticals (*radiotherapeutics/radiodiagnostics*)
- Combined company has 750+ employees, spanning discovery, development, manufacturing, regulatory, and sales in Japan



The Global Leader in the Discovery of Peptide Therapeutics

- **PeptiDream** (established in 2006) is largely credited with establishing the macrocyclic peptide field – high global reputation across the pharma industry.
- Collaborations with the majority of the world's pharmaceutical companies



Leading Targeted-radiopharmaceutical Position in Japan

- **PDRadiopharma** (established in 1968) is one of two radiopharmaceutical companies licensed to operate in Japan (currently sells 8 radiotherapeutic and 21 radiodagnostic products in Japan)
- Ideally positioned to capture a large share of the radiopharmaceutical field in Japan, while contributing through partnerships globally



PeptiDream

Revolutionizing Drug Discovery TSE Prime: 4587

★ HQ & Research Laboratory

★ New Research Building



PDRadiopharma

A PeptiDream Company

★ HQ

● Manufacturing and Research Sites

■ Sales Offices (8)

○ Kazusa Akademia Park New RI Manufacturing Plant

PDRadiopharma Tokyo HQ

PDRadiopharma Chiba Manufacturing Site (Sanmu City)



PDRadiopharma Ibaraki Lab




PDRadiopharma Kawasaki Lab



PeptiDream HQ

PeptiDream – The Epicenter of Peptide Drug Discovery

PeptiDream's Evolving Proprietary PDPS® Drug Discovery Platform



(2006)



Few big pharma
engaged in
peptide
drug discovery

(Today)



Every big pharma
engaged in peptide drug
discovery


PeptiDream has played a significant role in advancing Peptide Drug Discovery

PDRadiopharma: Current Key Products Overview



Current Key Marketed Products

Brain				
■ AMYViD®	PET	¹⁸ F	Visualization of beta amyloid plaques in the brain of patients with MCI or suspected to have dementia due to Alzheimer’s Disease	
■ TAUVID®	PET	¹⁸ F	Imaging Tau pathology in Alzheimer’s Disease	
■ Neurolite	SPECT	^{99m} Tc	Cerebral Blood Flow	
Heart				
■ MyoMIBG®	SPECT	¹²³ I	Heart Disease/ Pheochromocytoma/ Neuroblastoma/ PD/ DLB	
■ Cardiolite®	SPECT	^{99m} Tc	Heart Disease/ Hyperparathyroidism	
■ TI201	SPECT	²⁰¹ Tl	Heart Disease	
Bone				
■ Techne® MDP	SPECT	^{99m} Tc	Bone Scintigraphy	



Cancer

■ FDG	PET	¹⁸ F	Malignant Tumor/ Heart Disease/ Intractable Partial Epilepsy/ Large-vessel Vasculitis
■ Raiatt MIBG	-	¹³¹ I	MIBG avid Pheochromocytoma/ Paraganglioma/ Neuroblastoma

Thyroid

■ Sodium Iodide Capsule	-	¹³¹ I	Hyperthyroidism/ Primary and Metastatic Thyroid Cancer
■ Ultra-Techne Kow®	SPECT	^{99m} Tc	Thyroid Disease/ Brain Diseases/ Salivary Gland Disease

Kidney/ Urinary Tract

■ Techne® DTPA	SPECT	^{99m} Tc	Renal Scintigraphy
----------------	-------	-------------------	--------------------

Neuroendocrine

■ OctreoScan	SPECT	¹¹¹ In	Somatostatin Receptor Scintigraphy
--------------	-------	-------------------	------------------------------------

Total Solution Provider in Japan Radiopharmaceuticals Field

Radiopharmaceuticals Products



Diagnostics



- Provides total of 22 radiodiagnostic products

Therapeutics



- Provides total of 8 radiotherapeutic products

Injection System & Operational Support



Injection System



Portable Dosage Recorder Scheduling Assist



- ## INJECTOR/ DISPENSER
- Automated injection
 - Automated device that collects from multiple and aliquots desired volume

- Easily digitalize dosage history and actual dosage
- Nuclear medicine exam. scheduling

Software Solution




Image Analysis Solutions




- AMYViD
dedicated brain
imaging analysis
solution
- Cerebral blood
flow analysis
solution
- Myocardial blood
flow and function
analysis solution
- Bone scintigraphy
image analysis
solution

Management System




International Standards-Compliant Systems




- Medical information system designed for electronic recording, managing and optimizing medical radiation dose

Consolidated/Equity Method Applied Companies



Major Progress of PeptiDream's Equity Holdings



External Directors at PeptiDream



**Independent External Director
(Auditing Committee Member)**

Kiichiro Kamiya

- Joined PeptiDream in Mar 2025, after working at Hoechst Japan Ltd., Director and President of JSR Life Sciences Corporation, Director of MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., Senior Officer and Deputy General Manager of Life Sciences Division of JSR Corporation
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream



**Independent External Director
(Auditing Committee Member)**

Junko Utsunomiya (Attorney)

- Joined PeptiDream in Mar 2021, after working at Nagashima Ohno & Tsunematsu, Utsunomiya Shimizu & Haruki Management Legal Office as a founding partner
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream



**Independent External Director
(Auditing Committee Member)**

Yukinori Hanafusa (Certified Public Accountant)

- Joined PeptiDream in Sep 2017, after working at Aoyama Audit Corporation, Accounting Works Co., Ltd. as Founding Representative Director, ARCLAND SERVICE HOLDINGS CO., LTD as Director
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream



**Independent External Director
(Auditing Committee Member)**

Junko Nishiyama

- Joined PeptiDream in Mar 2025, after working at Lion Corporation, where she held several key positions including Director, Packaging Engineering Research Laboratories, R&D Headquarters; Director, CSR Promotion Dept.; Audit & Supervisory Board Member, etc.
- Outside Director (Member of the Audit Committee) of EBARA CORPORATION and Outside Audit & Supervisory Board Member of TODA CORPORATION (to present)
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Analyst Coverage

Company/ Organization	Analyst
Iwai Cosmo Securities Co., Ltd.	Kazuyoshi Saito
ACE Research Institute Inc.	Tomohiko Ikeno
SMBC Nikko Securities Inc.	Hiroshi Wada
SBI Securities Co., Ltd.	Ryuta Kawamura
Goldman Sachs Japan Co., Ltd.	Akinori Ueda
Jefferies (Japan) Limited	Miyabi Yamakita
Citigroup Global Markets Japan Inc.	Hidemaru Yamaguchi
Daiwa Securities Co. Ltd	Kazuaki Hashiguchi
Nomura Securities Co., Ltd.	Hiroyuki Matsubara
Marusan Securities Co., Ltd.	Tsuyoshi Ohno
Mizuho Securities Co., Ltd.	Yuriko Ishida

Forward-Looking Statements

This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors.

These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchange rates.

The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice.

This material is intended to provide information on our Group's business and is not intended to solicit investment in securities.

PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.



PeptiDream

Revolutionizing Drug Discovery